Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$247M |
| 2 |
Johnson & Johnson
JNJ
|
+$225M |
| 3 |
MON
Monsanto Co
MON
|
+$213M |
| 4 |
AET
Aetna Inc
AET
|
+$208M |
| 5 |
Broadcom
AVGO
|
+$176M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$227M |
| 2 |
Microsoft
MSFT
|
+$224M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$205M |
| 4 |
Nike
NKE
|
+$187M |
| 5 |
Pfizer
PFE
|
+$184M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 14.75% |
| 2 | Technology | 13.74% |
| 3 | Healthcare | 12.69% |
| 4 | Industrials | 11.51% |
| 5 | Consumer Discretionary | 8.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2376
Allient
ALNT
$1.87B
| $1.47M | ﹤0.01% |
102,900
+13,650
| +15% | +$190K |
|
|
TST
2377
DELISTED
TheStreet, Inc.
TST
| $1.46M | ﹤0.01% |
171,840
+7,540
| +5% | +$71K |
|
|
BKS
2378
DELISTED
Barnes & Noble
BKS
| $1.46M | ﹤0.01% |
130,666
-529,634
| -80% | -$6.07M |
|
2379
Compass Minerals
CMP
$1.11B
| $1.45M | ﹤0.01% |
+18,500
| New | +$1.41M |
|
|
TULP
2380
Bloomia Holdings
TULP
| $1.45M | ﹤0.01% |
84,614
+200
| +0.2% | +$3.14K |
|
2381
Kewaunee Scientific
KEQU
$105M
| $1.44M | ﹤0.01% |
59,000
+6,000
| +11% | +$141K |
|
|
NADL
2382
DELISTED
North Atlantic Drilling Ltd
NADL
| $1.44M | ﹤0.01% |
453,940
+13,300
| +3% | +$40.3K |
|
|
KLDX
2383
DELISTED
KLONDEX MINES LTD
KLDX
| $1.44M | ﹤0.01% |
307,300
+158,900
| +107% | +$788K |
|
2384
BCB Bancorp
BCBP
$162M
| $1.43M | ﹤0.01% |
110,000
+33,400
| +44% | +$404K |
|
|
TTPH
2385
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
| $1.43M | ﹤0.01% |
17,736
-18,714
| -51% | -$1.48M |
|
|
SALM
2386
DELISTED
Salem Media Group, Inc. Class A Common Stock
SALM
| $1.43M | ﹤0.01% |
228,500
-33,300
| -13% | -$197K |
|
|
JNP
2387
DELISTED
Juniper Pharmaceuticals, Inc. Common Stock
JNP
| $1.42M | ﹤0.01% |
254,300
+17,900
| +8% | +$98.3K |
|
|
LITS
2388
Lite Strategy Inc
LITS
$30.6M
| $1.42M | ﹤0.01% |
49,321
-9,432
| -16% | -$297K |
|
|
NEFF
2389
DELISTED
Neff Corporation
NEFF
| $1.42M | ﹤0.01% |
100,700
+81,800
| +433% | +$947K |
|
|
GTT
2390
DELISTED
GTT Communications, Inc.
GTT
| $1.42M | ﹤0.01% |
+49,300
| New | +$1.22M |
|
|
SPAN
2391
DELISTED
Span-America Medical Systems I
SPAN
| $1.42M | ﹤0.01% |
77,600
+5,199
| +7% | +$96K |
|
2392
Cumberland Pharmaceuticals
CPIX
$118M
| $1.41M | ﹤0.01% |
257,000
+9,900
| +4% | +$51.6K |
|
2393
Magnachip Semiconductor
MX
$137M
| $1.41M | ﹤0.01% |
228,131
+200,100
| +714% | +$1.36M |
|
2394
UMB Financial
UMBF
$11.5B
| $1.41M | ﹤0.01% |
18,276
-45,624
| -71% | -$3.17M |
|
2395
uniQure
QURE
$3.28B
| $1.41M | ﹤0.01% |
251,300
+15,950
| +7% | +$107K |
|
|
NTP
2396
DELISTED
Nam Tai Property Inc.
NTP
| $1.4M | ﹤0.01% |
189,184
-73,058
| -28% | -$556K |
|
2397
Fabrinet
FN
$20.4B
| $1.4M | ﹤0.01% |
34,700
-209,100
| -86% | -$8.72M |
|
2398
Pegasystems
PEGA
$5.35B
| $1.4M | ﹤0.01% |
77,648
-539,000
| -87% | -$9.01M |
|
2399
BBVA Argentina
BBAR
$3.14B
| $1.4M | ﹤0.01% |
80,116
-6,689
| -8% | -$125K |
|
2400
Astec Industries
ASTE
$996M
| $1.39M | ﹤0.01% |
+20,645
| New | +$1.29M |
|
Similar funds
Jim Simons's Q4 2016 Portfolio in Review
As of Q4 2016, Jim Simons held 3,715 positions worth $63.2B, up 12% from $56.6B the previous quarter. Its ten largest holdings account for 7.2% of the portfolio.
Jim Simons deployed $5.07B of net new capital in Q4 2016, opening 418 new positions and adding to 1,792 existing holdings. Its largest new stake was Broadcom: 10,144,960 shares worth $179M.
By sector, the portfolio is most concentrated in Financials at 15% of assets, up from 12% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $227M trimmed.
- Jim Simons's largest Q4 2016 buy was Broadcom: 10,144,960 shares worth $179M.
- Jim Simons added most to Gilead Sciences in Q4 2016, an estimated $247M increase.
- Jim Simons's biggest Q4 2016 reduction was Bristol-Myers Squibb, cutting an estimated $227M.
- Jim Simons fully exited Alphabet (Google) Class C in Q4 2016, selling an estimated $205M.
- Jim Simons's ten largest holdings make up 7.2% of its $63.2B portfolio in Q4 2016.
- Jim Simons opened 418 new positions and closed 494 in Q4 2016.
- Jim Simons's portfolio value rose 12% quarter-over-quarter to $63.2B.
Based on Renaissance Technologies's 13F filing for Q4 2016, filed 13 Feb 2017.